The health system said it offered a “historic” 21.5% raise as part of a new contract, but it’s been unable to reach an agreement with union officials. Workers are expected to walk off the job starting Jan. 26. 

Traditional fee-for-service Medicare saw a slight dip in improper payments, which are usually associated with documentation errors and now outright fraud. CMS also released data on Medicaid and the CHIP program. 

The Missouri complaint mirrors those brought by the Federal Trade Commission, the state of Texas and Philadelphia-based Jefferson Health, among others, in that it’s focused on alleged collusion between pharmacy benefit managers and drug companies to control the price of insulin. 

Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates. 

President Trump’s outline is largely an exercise in thinking out loud since it can’t propel anything consequential without legislative action in Congress. Still, the plan—and the reactions it’s eliciting—warrant a look. 

The insurer is planning to reduce reimbursement timelines for hospitals in Oklahoma, Idaho, Minnesota and Missouri from 30 days to 15. The details are unclear, but the company said the framework could extend nationwide.

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions.